Guided Therapeutics (GTHP) Depreciation & Amortization (CF) (2011 - 2025)

Guided Therapeutics (GTHP) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $3000.0 in Q4 2025.

• For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 50.0% year-over-year to $3000.0; the trailing twelve-month figure through Dec 2025 stood at $10000.0 (up 11.11% YoY), and the FY2025 full-year result was $10000.0, up 11.11% from the prior year.
• Depreciation & Amortization (CF) grew to $3000.0 in Q4 2025, from $2000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $3000.0 in Q4 2022 to a low of $1000.0 in Q3 2022.
• A 4-year average of $2285.7 and a median of $2000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Peak annual rise in Depreciation & Amortization (CF) reached 100.0% in 2023, while the deepest fall reached 33.33% in 2023.
• Tracing GTHP's Depreciation & Amortization (CF) over 4 years: stood at $3000.0 in 2022, then sank by 33.33% to $2000.0 in 2023, then changed by 0.0% to $2000.0 in 2024, then jumped by 50.0% to $3000.0 in 2025.
• Business Quant data shows GTHP's Depreciation & Amortization (CF) at $3000.0 in Q4 2025, $2000.0 in Q3 2025, and $3000.0 in Q2 2025.